Previous Close | 56.73 |
Open | 56.80 |
Bid | 57.23 x 0 |
Ask | 57.29 x 0 |
Day's Range | 56.57 - 57.50 |
52 Week Range | 53.28 - 66.01 |
Volume | |
Avg. Volume | 61,698 |
Market Cap | 2.26T |
Beta (5Y Monthly) | 0.72 |
PE Ratio (TTM) | 22.45 |
EPS (TTM) | 2.55 |
Earnings Date | N/A |
Forward Dividend & Yield | 1.46 (2.40%) |
Ex-Dividend Date | May 23, 2022 |
1y Target Est | N/A |
Immix Biopharma Inc (NASDAQ: IMMX) announced positive interim data from an animal study in Soft Tissue Sarcoma (STS). STS is a broad term for cancers that start in soft tissues (muscle, tendons, fat, lymph and blood vessels, and nerves). After one treatment cycle, ImmixBio's lead candidate IMX-110 produced 75% survival vs. 0% survival for trabectedin in a connective tissue cancer Soft Tissue Sarcoma (STS) mice study. Trabectedin is sold as Yondelis by Janssen, a Johnson & Johnson (NYSE: JNJ) com
We discuss areas that could outperform in the current market environment.
Companies could be returning trillions to shareholders. Here’s how to accept it.